Pinealon (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: dosing is daily during the 10 to 20 day subcutaneous course, followed by an extended off-cycle of 3 to 6 months. The short course structure follows the Khavinson school: brief exposure is proposed to trigger gene expression changes that persist between cycles, so continuous use is not the established pattern. Morning dosing is standard when cognitive support is the goal, and evening dosing is used when sleep quality is the focus; the same peptide serves both purposes and only the timing changes the emphasis. Some protocols pair morning Pinealon with evening Epitalon to cover both neuronal protection and the circadian and telomere targets. The subcutaneous route is given as one injection per day, with sites rotated systematically across abdomen, thighs, and upper arms to avoid lipohypertrophy. At 10 mg/mL a 1 mg dose is 10 units (0.10 mL) and a 2 mg dose is 20 units (0.20 mL), so every dose in this protocol fits one U-100 insulin syringe and none of them split across two injections. The 2 mg dose can be taken as a single morning injection of 20 units (0.20 mL) or split into two injections of 10 units (0.10 mL), morning and evening. Oral and sublingual routes need no reconstitution and carry no units figure: the oral trial dose is 0.2 mg twice daily for 20 to 30 days, capsules are about 0.4 mg daily for 30 days, and sublingual drops are 5 to 6 drops held under the tongue for 30 to 60 seconds, 3 to 4 times daily for about a month.

Results Timeline

Sequence described in the research record. Individual response varies.

• Days 1 to 20, or 10 to 14 days on a shorter course: the active subcutaneous course, one injection daily in the morning for cognitive support or in the evening when sleep quality is the focus.
• Through the course: effects are sub-perceptual. Antioxidant gene upregulation does not produce noticeable acute sensations, so no change in sharpness or focus is expected at any point.
• Occasional early effects: mild transient headaches, vivid dreams that are generally neutral or positive, uncommon nausea that is more common at the higher dose, and injection-site reactions on the subcutaneous route.
• After the course ends: the mechanism is proposed to persist between cycles, since brief exposure is said to trigger gene expression changes rather than to maintain a continuous signal.
• Months 3 to 6: the off-cycle break runs its course and the next 10 to 20 day course begins, which puts most research use at 2 to 3 courses per year.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 1 mg = 10 units (0.10 mL) and 2 mg = 20 units (0.20 mL), each of which fits a single U-100 syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• At 1.0 mL per 10 mg vial, one reconstituted vial holds 10 doses of 1 mg or 5 doses of 2 mg, so a 14 day course at 1 mg opens a second vial partway through and a 14 day course at 2 mg works through three.

Supplies Needed

Planning below is based on a 14 day subcutaneous course at 1 mg per day, which is 7 mg in a full week, with 2 to 3 courses per year.

Peptide Vials (Pinealon, 10 mg vial):

• A 14 day course at 1 mg per day is 14 mg, which is about 2 vials of 10 mg; the same course at 2 mg per day is 28 mg, or about 3 vials, and an annual budget of 3 courses at 1 mg for 14 days is about 6 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes at one injection daily, since at 10 mg/mL a 1 mg dose is 10 units (0.10 mL) and a 2 mg dose is 20 units (0.20 mL), so a 30 or 50 unit syringe covers either.
• Full course: 14 syringes across a 14 day course, or about 42 across an annual budget of 3 courses; splitting the 2 mg dose into morning and evening injections doubles that to 2 syringes per day.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL of bacteriostatic water, so one 10 mL bottle covers 10 vials, which is well past the 2 to 6 vials an annual set of courses requires.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin.
• Full course: 28 swabs across a 14 day course and about 84 across an annual set of 3 courses, so one 100 count box covers the year.

Important Notes

Practical considerations for consistency and safety.

• Despite the name, Pinealon is not from the pineal gland. It was isolated from brain cortex extract during Cortexin research, and the name refers to proposed target effects rather than source tissue.
• This is neuroprotection, not cognitive enhancement. Effects are sub-perceptual, and antioxidant gene upregulation does not produce noticeable acute sensations. Coming from Semax or stimulants, the honest expectation is to feel nothing. Pinealon is protective infrastructure rather than a performance tool.
• Short courses, not chronic use. Subcutaneous courses run 10 to 20 days and oral courses about 30 days, cycled every 3 to 6 months. Continuous long-term use has not been studied and is not the established approach.
• Oral bioavailability is the unusual feature. Most peptides require injection because GI enzymes destroy them, and the tripeptide is small enough to survive GI transit. The 72-patient TBI trial used 0.2 mg twice daily by mouth, and sublingual drops at 5 to 6 drops 3 to 4 times daily are also viable, so the oral and sublingual routes are genuine alternatives rather than weaker substitutes. The subcutaneous route remains the most direct.
• Contraindications and stacking. A seizure disorder contraindication is specifically noted for Pinealon, and it is not used with active or controlled seizure conditions. Other contraindications are pregnancy or breastfeeding with no safety data, known peptide hypersensitivity, and active neurological conditions where data is insufficient. Named stacking partners are Epitalon for upstream and downstream brain aging coverage, Semax for acute cognitive output alongside protection, and P21, which builds new neurons while Pinealon protects them. A theoretical caspase-3 nuance is worth flagging: Pinealon reduces caspase-3 expression as part of its anti-apoptotic effect, and caspase-3 also helps eliminate damaged or pre-cancerous cells, which raises an unstudied question about suppressing apoptosis in cells that should die. This is an awareness flag, not an established risk.
• Regulatory Note: the evidence position is thinner than Epitalon's. All research comes from the single Khavinson institute across 196 patents and commercial entities, roughly half of it published in Russian only, with no independent replication in more than 40 years, no ClinicalTrials.gov registrations, and no human clinical trials beyond the single 72-patient TBI cognitive study. Unlike Epitalon, which received the 2025 Brunel cellular validation, Pinealon has zero Western independent confirmation, and the master sheet records no approval status and no WADA status for this compound. For neuroprotection specifically, established interventions such as exercise, sleep optimization, NAD+, MOTS-c, and omega-3s carry stronger evidence-to-risk ratios. For research use only; not for human consumption.

How This Works

Pinealon's proposed mechanism centers on the brain's specific oxidative-stress vulnerability: 2% of body weight consumes about 20% of total oxygen, generating reactive oxygen species (ROS) while neurons hold limited antioxidant reserves and are largely non-replaceable. Four interconnected mechanisms are proposed. First, antioxidant gene upregulation: rather than directly scavenging free radicals, Pinealon increases cellular production of endogenous antioxidant enzymes including SOD (superoxide dismutase), glutathione peroxidase (GPx), and catalase, and in cell culture Pinealon-treated neurons showed antioxidant enzyme levels comparable to hypoxia-resistant animals. Second, MAPK/ERK timing modulation: under oxidative stress ERK1/2 normally activates within about 2.5 minutes, often triggering apoptosis, and Pinealon delays that activation to about 20 minutes, shifting the cellular response toward survival pathways instead of cell death. Third, excitotoxicity protection: in glutamate overstimulation models, Pinealon-treated neurons showed increased survival, likely through the same antioxidant and stress-response pathways. Fourth, a DNA interaction hypothesis: molecular studies suggest the tripeptide may bind DNA at gene promoter regions and influence transcription directly, which is unconventional for such a short peptide and requires independent validation. The mechanism is biologically plausible and internally consistent across the Khavinson corpus, but the entire body of work originates from one institute with commercial interests and has not been independently replicated.

Benefits & Side Effects

Observations from the published record.

• Neuroprotection under oxidative stress (cell culture): increased viability and reduced apoptotic markers in cortical and hippocampal neurons exposed to ROS, alongside SOD2 and GPx1 transcriptional upregulation, an effect at the gene expression level rather than enzyme activity alone.
• MAPK/ERK timing shift (cell culture): ERK1/2 activation delayed from about 2.5 minutes to about 20 minutes under oxidative stress, favoring survival pathways, with ischemia protection also reported in rodents when blood flow to brain tissue is temporarily restricted.
• Cognitive preservation in aged rodents: chronic administration preserved learning and memory and correlated with reduced markers of age-related neurodegeneration in hippocampal tissue.
• The 72-patient TBI cognitive trial is the only human data: 0.2 mg twice daily by mouth for 20 to 30 days showed cognitive improvements in patients with traumatic brain injury consequences. Single trial, no replication.
• Community-reported subjective effects are sleep quality improvements, HRV improvements, and subtle mood and concentration changes, with most reporting sub-perceptual effects or none. What is not reported: acute cognitive sharpness, which this is the wrong tool for, along with cardiovascular effects, sedation, and withdrawal.
• Side effects: mild headaches (occasional, transient); nausea (uncommon, more common at higher doses); vivid dreams (occasional, generally neutral or positive); rare paradoxical mild anxiety, where the practice is to discontinue if it persists; and injection-site reactions on the subcutaneous route.

Lifestyle Factors

Complementary strategies for best outcomes.

• Sleep 7 to 9 hours nightly, since most neural repair and antioxidant gene expression happens during sleep and the protocol assumes adequate sleep as substrate.
• Aerobic exercise independently upregulates BDNF and antioxidant defenses, complementing the gene expression direction Pinealon proposes, while omega-3 fatty acids (EPA and DHA) protect neural membranes from oxidation.
• Reduce chronic stress and minimize alcohol during cycles: cortisol opposes the antioxidant gene expression the protocol supports, and ethanol metabolism generates ROS directly against it.
• Use the network during a course through novel learning, problem-solving, and social engagement, and put the established levers in place first, since sleep optimization, exercise, omega-3s, and NAD+ carry stronger evidence-to-risk ratios than Pinealon.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Pinealon antioxidant and MAPK modulation: SOD2 and GPx1 upregulation, ERK1/2 activation delayed under oxidative stress (PubMed 21978084).
2. EDR peptide neuroprotection: caspase-3 and p53 reduction, viability under excitotoxicity, 72-patient TBI cognitive trial at 0.2 mg twice daily by mouth (PMC7795577).
3. Khavinson peptide bioregulation: 40 year research program, peptide-DNA binding, epigenetic signaling at low concentrations (PubMed 19830583).
4. Related peptide review: 2025 overview of Khavinson bioregulators including safety data gaps (PMC11943447).